Harnessing the power of protein aggregation
Aelin Therapeutics is founded by VIB and its partner universities KULeuven, VUB and UGent in 2017. Their final purpose is to create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology, branded Pept-insTM, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The company received a 27M€ Series A financing to bring a first Pept-in product to the market.